---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-095507"
form_type: "8-K/A"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:50:19.744381+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Estrella Immunopharma enters consulting agreement with chairperson's company Cofame

## Summary
- Estrella Immunopharma entered a Consulting Agreement with Cofame Investment Management, owned by Chairperson Hong Zhang, for advisory services up to three days per week.
- Cofame receives $55,000 upfront and an annual fee of $220,000; Hong Zhang granted option to purchase 1,000,000 shares under the 2023 Omnibus Incentive Plan.
- Option vests 25% on August 1, 2025, with the remaining 75% vesting monthly over 36 months, contingent on continued service.
- The Audit Committee reviewed and approved the agreement as a related-party transaction.

## SEC filing metadata
- accession: 0001213900-24-095507
- form_type: 8-K/A
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390024095507/0001213900-24-095507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390024095507/ea022043401-8ka_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-095507
- JSON: https://secwatch.observer/filing/0001213900-24-095507.json
- Plain text: https://secwatch.observer/filing/0001213900-24-095507.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.